FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028438234> ?p ?o ?g. }

• W3028438234 endingPage "104883" @default.
• W3028438234 startingPage "104883" @default.
• W3028438234 abstract "Xinyue capsule, a patented Chinese herbal medicine, has been used to manage coronary artery disease (CAD) for over a decade in China, but whether it can further reduce risk of cardiovascular events beyond conventional treatment is unknown. In this multicenter, randomized, placebo-controlled trial, we randomly assigned patients with stable CAD who underwent percutaneous coronary intervention (PCI) within the preceding 3-12 months to receive Xinyue capsule (100 mg panax quinquefolius saponins, three times a day) or placebo for 24 weeks in addition to conventional treatment. The primary endpoint was a composite that included cardiac death, nonfatal myocardial infarction and urgent revascularization with either PCI or coronary artery bypass grafting. The secondary composite endpoints included stroke, re-hospitalization due to acute coronary syndrome (ACS), pulmonary embolism, peripheral vascular events and all-cause mortality. Quality of life was assessed using a 36-item Short-Form Health Survey (SF-36). A total of 1054 participants were included in the analyses. The median follow up was 1 year. The primary endpoint events occurred in 16 patients (3.02%) in the Xinyue group and 34 patients (6.49%) in the placebo group (hazard ratio [HR] 0.455, 95% confidence interval [CI] 0.25 to 0.825; P = 0.009). Secondary end-point events occurred in 5.47% of patients in the Xinyue group and 10.31% in the placebo group (HR 0.515, 95% CI 0.328 to 0.809; P = 0.004). SF-36 subscale scores at 12 months were significantly higher in the Xinyue group than placebo group for general health (P = 0.048) and vitality (P = 0.008). In patients with stable CAD after PCI within the preceding 3 to 12 months, Xinyue capsule added on conventional treatment reduced the incidence of primary composite endpoint (cardiac death, nonfatal myocardial infarction and urgent revascularization)." @default.
• W3028438234 created "2020-05-29" @default.
• W3028438234 creator A5002246354 @default.
• W3028438234 creator A5016583762 @default.
• W3028438234 creator A5030212562 @default.
• W3028438234 creator A5037198661 @default.
• W3028438234 creator A5048047268 @default.
• W3028438234 creator A5062246119 @default.
• W3028438234 creator A5065077694 @default.
• W3028438234 creator A5069977930 @default.
• W3028438234 creator A5075495109 @default.
• W3028438234 creator A5080252238 @default.
• W3028438234 creator A5081822445 @default.
• W3028438234 creator A5088214633 @default.
• W3028438234 date "2020-08-01" @default.
• W3028438234 modified "2023-10-16" @default.
• W3028438234 title "Xinyue Capsule in patients with stable coronary artery disease after percutaneous coronary intervention: a multicenter, randomized, placebo-controlled trial" @default.
• W3028438234 cites W1484726395 @default.
• W3028438234 cites W1936833235 @default.
• W3028438234 cites W1973695525 @default.
• W3028438234 cites W1975842139 @default.
• W3028438234 cites W2043438355 @default.
• W3028438234 cites W2057221768 @default.
• W3028438234 cites W2112863991 @default.
• W3028438234 cites W2125702693 @default.
• W3028438234 cites W2133924558 @default.
• W3028438234 cites W2148352532 @default.
• W3028438234 cites W2160414137 @default.
• W3028438234 cites W2166351234 @default.
• W3028438234 cites W2169226612 @default.
• W3028438234 cites W2193930631 @default.
• W3028438234 cites W2340015041 @default.
• W3028438234 cites W2601984476 @default.
• W3028438234 cites W2624747153 @default.
• W3028438234 cites W2892237085 @default.
• W3028438234 cites W4292856638 @default.
• W3028438234 doi "https://doi.org/10.1016/j.phrs.2020.104883" @default.
• W3028438234 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32446979" @default.
• W3028438234 hasPublicationYear "2020" @default.
• W3028438234 type Work @default.
• W3028438234 sameAs 3028438234 @default.
• W3028438234 citedByCount "13" @default.
• W3028438234 countsByYear W30284382342020 @default.
• W3028438234 countsByYear W30284382342021 @default.
• W3028438234 countsByYear W30284382342022 @default.
• W3028438234 countsByYear W30284382342023 @default.
• W3028438234 crossrefType "journal-article" @default.
• W3028438234 hasAuthorship W3028438234A5002246354 @default.
• W3028438234 hasAuthorship W3028438234A5016583762 @default.
• W3028438234 hasAuthorship W3028438234A5030212562 @default.
• W3028438234 hasAuthorship W3028438234A5037198661 @default.
• W3028438234 hasAuthorship W3028438234A5048047268 @default.
• W3028438234 hasAuthorship W3028438234A5062246119 @default.
• W3028438234 hasAuthorship W3028438234A5065077694 @default.
• W3028438234 hasAuthorship W3028438234A5069977930 @default.
• W3028438234 hasAuthorship W3028438234A5075495109 @default.
• W3028438234 hasAuthorship W3028438234A5080252238 @default.
• W3028438234 hasAuthorship W3028438234A5081822445 @default.
• W3028438234 hasAuthorship W3028438234A5088214633 @default.
• W3028438234 hasConcept C126322002 @default.
• W3028438234 hasConcept C127413603 @default.
• W3028438234 hasConcept C141071460 @default.
• W3028438234 hasConcept C142724271 @default.
• W3028438234 hasConcept C164705383 @default.
• W3028438234 hasConcept C168563851 @default.
• W3028438234 hasConcept C203092338 @default.
• W3028438234 hasConcept C204787440 @default.
• W3028438234 hasConcept C207103383 @default.
• W3028438234 hasConcept C27081682 @default.
• W3028438234 hasConcept C2777698277 @default.
• W3028438234 hasConcept C2778213512 @default.
• W3028438234 hasConcept C2779464278 @default.
• W3028438234 hasConcept C2780400711 @default.
• W3028438234 hasConcept C2780645631 @default.
• W3028438234 hasConcept C44249647 @default.
• W3028438234 hasConcept C45393284 @default.
• W3028438234 hasConcept C500558357 @default.
• W3028438234 hasConcept C71924100 @default.
• W3028438234 hasConcept C78519656 @default.
• W3028438234 hasConceptScore W3028438234C126322002 @default.
• W3028438234 hasConceptScore W3028438234C127413603 @default.
• W3028438234 hasConceptScore W3028438234C141071460 @default.
• W3028438234 hasConceptScore W3028438234C142724271 @default.
• W3028438234 hasConceptScore W3028438234C164705383 @default.
• W3028438234 hasConceptScore W3028438234C168563851 @default.
• W3028438234 hasConceptScore W3028438234C203092338 @default.
• W3028438234 hasConceptScore W3028438234C204787440 @default.
• W3028438234 hasConceptScore W3028438234C207103383 @default.
• W3028438234 hasConceptScore W3028438234C27081682 @default.
• W3028438234 hasConceptScore W3028438234C2777698277 @default.
• W3028438234 hasConceptScore W3028438234C2778213512 @default.
• W3028438234 hasConceptScore W3028438234C2779464278 @default.
• W3028438234 hasConceptScore W3028438234C2780400711 @default.
• W3028438234 hasConceptScore W3028438234C2780645631 @default.
• W3028438234 hasConceptScore W3028438234C44249647 @default.
• W3028438234 hasConceptScore W3028438234C45393284 @default.
• W3028438234 hasConceptScore W3028438234C500558357 @default.
• W3028438234 hasConceptScore W3028438234C71924100 @default.

• next